Introduction Human papillomavirus (HPV) infection, which poses significant disease burden,
is decreasing following implementation of vaccination programs. Synthesized evidence on …

Cervical cancer is the fourth largest malignant tumor among women in the world. Human
papillomavirus (HPV) infection can lead to cervical intraepithelial neoplasia (CIN) and …

Triage strategies are needed for primary human papillomavirus (HPV)‐based cervical
cancer screening to identify women requiring colposcopy/biopsy. We assessed the …

Cervical cancer screening has enabled a decrease in the incidence and mortality of cervical
cancer. Various screening modalities have been studied to date. In many countries …

Background The aim of the study was to investigate the risk of human papillomavirus (HPV)
genotyping particularly vaccine genotypes and multiple infections for cervical precancer and …

Cervical cancer, primarily caused by high-risk human papillomavirus (HR-HPV) types 16
and 18, is a major global health concern. Persistent HR-HPV infection can progress from …

Simple Summary This study aimed at assessing HPV16 and HPV18 viral loads to predict the
development of cervical high-grade lesion. Among 885 women positive for hrHPV and …

Objective strategies are required in cervical cancer screening. We have identified several
DNA methylation markers with high sensitivity and specificity to detect cervical intraepithelial …

Objectives Extended high-risk human papillomavirus (hrHPV) genotype testing has recently
been introduced in routine cervical cancer screening. Changes in national and regional …

While cervix screening using cytology is recommended at 2‐to 3‐year intervals, given the
increased sensitivity of human papillomavirus (HPV)‐based screening to detect precancer …